Results 161 to 170 of about 7,693 (199)

Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer. [PDF]

iScience
Westaby D, Jiménez-Vacas JM, Figueiredo I, Welti J, Gurel B, Bogdan D, Buroni L, Neeb AJ, Rekowski J, Padilha A, Das S, Taylor J, Zeng W, Waldron N, Goldsmith T, Hobern E, Gabel F, Pandell N, Miranda S, Lambros MB, Carreira S, Swain A, Yuan W, Balk SP, Bezzi M, de Bono JS, Sharp A.   +26 more
europepmc   +1 more source

Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature. [PDF]

Ann Hematol
Dereme J, Segot A, Nabergoj M, Dewarrat N, Basset V, Blum S, Tsilimidos G.   +6 more
europepmc   +1 more source

A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. [PDF]

Cancer Chemother Pharmacol
Scott SC, Farago A, Lai WV, Zahurak M, Rudek MA, Murray J, Carducci MA, Uziel T, Takebe N, Gore SD, Rudin CM, Hann CL.   +11 more
europepmc   +1 more source

Moving forward from spleen response as an endpoint in randomized controlled trials in myelofibrosis. [PDF]

Haematologica
Van Dijck R, Schnog JB, Te Boekhorst PAW.   +2 more
europepmc   +1 more source

<i>In silico</i> evaluation of vitamin D3 as a dual inhibitor of CDK2 and Bcl-2 in colorectal cancer. [PDF]

Open Vet J
Shobahah J, Wahyuningsih SPA, Winarni D, Herdiansyah MA, Aly MAN.   +4 more
europepmc   +1 more source

The Yin and Yang of cellular senescence in ischemia-induced myocardial injury. [PDF]

Trends Cardiovasc Med
Wolff von Gudenberg R, Iske J, Roeschl T, Stawowy P, Kirkland JL, Ruhparwar A, Tullius SG.   +6 more
europepmc   +1 more source

A Macrophage-Derived 7-Gene Signature Predicts Prognosis and Therapeutic Response in Hepatocellular Carcinoma. [PDF]

IUBMB Life
Li X, Li Z, Zhai J, Zou B.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice

Journal of Cardiovascular Pharmacology, 2020
Abstract: Navitoclax, which is a type of senolytic drug, selectively eliminates senescent cells. This study aimed to evaluate the therapeutic potential of navitoclax in treatment of angiotensin II (Ang II)-induced heart failure in mice. Navitoclax or vehicle was administrated in mice with Ang II-induced heart failure.
Kangni Jia, Ao Liu, Lin Lu
exaly   +3 more sources